Summary of COVID-19 MAS825 studies

1. Hakim et al., Efficacy and safety of MAS825 (anti-IL-1β/IL-18) in COVID-19 patients with pneumonia and impaired respiratory function

138 patient MAS825 late treatment RCT: 16% higher mortality (p=0.59) and 7% worse recovery (p=0.7).
RCT 138 hospitalized COVID-19 patients with pneumonia showing no significant difference in mortality or APACHE II scores with MAS825 (anti-IL-1β/IL-18 monoclonal antibody) compared to placebo.
Jun 2023, Clinical and Experimental Immunology, https://academic.oup.com/cei/advance-article/doi/10.1093/cei/uxad065/7203697, https://c19p.org/hakim